Levofloxacin

Levofloxacin is a fluoroquinolone antibiotic that treats bacterial infections by inhibiting DNA gyrase and topoisomerase IV, enzymes required for bacterial DNA replication.

DNA gyrase: A bacterial enzyme that relieves DNA supercoiling during replication and transcription. Levofloxacin traps this enzyme on DNA, causing breaks that damage bacterial chromosomes.
Community-acquired pneumonia: Pneumonia acquired outside hospitals or long-term care facilities. Levofloxacin is an option for selected cases, including some patients needing broad respiratory coverage.
Moxifloxacin: A fluoroquinolone antibiotic used mainly for respiratory and other infections. Unlike levofloxacin, moxifloxacin is not suitable for urinary infections because urinary concentrations are low.
Ofloxacin: A racemic fluoroquinolone antibiotic containing two mirror-image molecular forms. Levofloxacin is the more active S-enantiomer isolated from ofloxacin.
Antimicrobial stewardship: Coordinated practices that improve antimicrobial use and limit avoidable resistance and harm. Stewardship reserves levofloxacin for cases where its benefits justify broad-spectrum exposure.
Topoisomerase IV: A bacterial enzyme that separates interlinked daughter chromosomes after DNA replication. Levofloxacin inhibits this second target, especially in many Gram-positive bacteria.
Urinary tract infection: An infection involving the bladder, urethra, ureters, or kidneys. Levofloxacin reaches urinary tissues, though resistance and safer alternatives often guide choices.
Ciprofloxacin: A fluoroquinolone antibiotic with strong activity against many Gram-negative bacteria. Ciprofloxacin generally has stronger antipseudomonal activity, while levofloxacin offers broader pneumococcal activity.
Chirality: The property of a structure being distinguishable from its mirror image. Levofloxacin’s stereochemistry gives it greater antibacterial activity than the other ofloxacin enantiomer.
Black box warning: The strongest safety warning required on prescription-drug labeling in the United States. Fluoroquinolone labeling warns of disabling and potentially permanent adverse effects.

Linked from 3 pages